Vanguard Capital Management
SGP

Vanguard Capital Management’s SpyGlass Pharma SGP Stock Holding History

Vanguard Capital Management’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.67M Sell
434,423
-390
-0.1% -$8.46K ﹤0.01% 2834
2026
Q1 		$11.3M Buy
+434,813
New +$11.7M ﹤0.01% 2667

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's SGP Position: Q2 2026 in Review

Vanguard Capital Management reduced its SpyGlass Pharma (SGP) stake by 0.09% in Q2 2026, selling an estimated $8.46K and leaving 434,423 shares worth $9.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2834.

Vanguard Capital Management first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. The position peaked at $11.3M in Q1 2026. 43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Vanguard Capital Management held 434,423 shares of SpyGlass Pharma worth $9.67M as of Q2 2026.
  • Vanguard Capital Management sold 390 SpyGlass Pharma shares in Q2 2026, an estimated $8.46K.
  • SpyGlass Pharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2834 holding.
  • Vanguard Capital Management first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's SpyGlass Pharma position peaked at $11.3M in Q1 2026.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.